[Comparative characteristics of hemostasis system in patients with endstage renal disease admitted for urgent and elective hemodialysis].

Aim: To evaluate parameters of hemostasis system in patients with end-stage renal disease (ESRD) with consideration of elective or urgent start of dialysis treatment.

Material And Methods: A total of 47 patients with ESRD entered the study. They were divided into two groups depending on urgent (group 1) or elective (group 2) start of hemodialysis.

[Cryoapheresis in the treatment of patients with cryoglobulinemic mesangiocapillary glomerulonephritis and acute kidney failure].

Aim: To assess cryoapheresis (CA) efficacy in the treatment of cryoglobulinemic glomerulonephritis (CG) with acute renal failure (ACR).

Material And Methods: Ten 34-64-year-old CG patients with associated HCV infection and symptoms of ACR (diuresis under 500 ml/day, serum creatinin 1.6-8.

[Intermittent hemofiltration in the treatment of acute kidney failure in glomerulonephritis patients].

Intermittent hemofiltration (IH) was used in the treatment of acute renal failure (ARF) in 11 glomerulonephritis patients with nephrotic syndrome. IH was found effective in the above patients as it provides fast relief of interstitial edema of the essential for life organs (the kidneys, liver, lungs, etc.), control of plasma urea and potassium.

[The use of extracorporeal blood purification for the treatment of cardiac rhythm disorders].

Hemosorption and plasmapheresis were used in 26 patients with episodes of atrial fibrillation and extrasystoles. A response lasting 4 +/- 0.9 months was registered in 80% of cases.

[The use of hemosorption and plasmapheresis for treating cardiac arrhythmias (a preliminary report)].

The authors present pilot experience in extracorporeal blood purification (hemosorption, plasmapheresis) aimed at correction of cardiac arrhythmia. Seven responders of 8 patients treated had less frequent episodes of cardiac fibrillation the severity of which decreased, they suffered no more from high-grade extrasystoles, were put on reduced doses of antiarrhythmic drugs. The response is attributed to improvement of blood rheology and elimination of arrhythmogenic substances.

[Plasmapheresis in the treatment of rapidly progressing glomerulonephritis].

Twenty patients with rapidly progressing glomerulonephritis (RPGN) aged 16-50 underwent plasmapheresis (PA) as adjuvant to immunodepressants. Of these, 9 patients had lupus, 4 Bright RPGN, 4 and 3 patients combined glomerulonephritis with hemorrhagic vasculitis and Wegener granulomatosis, respectively. A total of 130 procedures were performed (3-13 per each patient).

[Acute kidney failure in patients with chronic glomerulonephritis].

The causes of acute renal failure (ARF) and results of its treatment are analyzed in 34 patients aged 15 to 51 years with exacerbation of chronic glomerulonephritis (CGN). Of these, 20 patients presented with lupoid GN, 11 with Bright's GN, and 3 had GN associated with systemic vasculitis (2 of them also had mixed cryoglobulinemia). All the patients underwent clinical treatment that lasted from January 1, 1986 to December 31, 1990.

[The partial recovery of kidney function in chronic uremia patients during hemodialysis treatment].

Out of 432 patients placed on the treatment with hemodialysis (HD) for terminal renal failure (TRF) at the All-Union Nephrologic Center from January 1, 1978 to December 31, 1987, 17 patients manifested partial recovery of renal function, which enabled dialysis treatment to be discontinued for a time. Among the 17 patients with noticeable improvement of renal function, 8 presented with lupoid rapid-progressing glomerulonephritis (RPGN), 2 with RPGN associated with hemorrhagic vasculitis, 1 with idiopathic RPGN, 4 with chronic glomerulonephritis (CGN), 1 with chronic pyelonephritis, and 1 with polycystic kidneys. In 11 patients with RPGN, the rate of renal failure progression, expressed by the regression coefficient, was much higher among those in whom HD treatment was discontinued that in the group of patients without renal function recovery.

[Plasmapheresis in the treatment of rapidly progressing glomerulonephritis].

The authors are of the opinion that plasmapheresis (PP) combined with immunosuppressant therapy is an effective and a relatively safe method for the treatment of rapidly progressing glomerulonephritis (RPGN). Introduction of PP in multimodality treatment of RPGN made it possible to arrest rapidly progressing renal failure in all 6 treated patients. After PP treatment was over, renal function was recovered completely in 3 patients.